Loading organizations...
Exosomm is a biotechnology and food technology company that produces bioactive milk exosomes at an industrial scale from cow milk whey to develop specialized medical food formulas. The organization utilizes a proprietary, chemical-free process to extract nano-sized vesicles that deliver microRNAs, proteins, and lipids designed to support immune regulation, gut health, and anti-inflammatory responses. Operating with an annual production capacity of 200 metric tons, the company formulates stable powders with a shelf life exceeding one year. Exosomm initially targets the $20.3 billion inflammatory bowel disease market and the broader $23 billion medical foods sector, operating with financial backing from investors including Galil Ofek Innovation. The enterprise plans to eventually expand its clinical applications into nutraceuticals, functional nutrition, and skincare products for broader consumer use. Exosomm was established by co-founders Netta Granot and Regina Golan-Gerstl.
Exosomm has raised $2.0M across 1 funding round.
Exosomm has raised $2.0M in total across 1 funding round.
Exosomm has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $2M Seed | — | Alumni Ventures, B Capital Group, Prithvi Ventures, SOSV, Vishal RAO | Announced |
Exosomm has raised $2.0M in total across 1 funding round.
Exosomm's investors include Alumni Ventures, B Capital Group, Prithvi Ventures, SOSV, Vishal Rao.
Exosomm is a BioTech-FoodTech startup pioneering the world's first commercial platform for producing bioactive milk exosomes at industrial scale, with a shelf life exceeding one year.[1][2] The company develops nutritional solutions derived from cow milk whey exosomes—nano-sized vesicles carrying microRNAs, proteins, and lipids that support immune regulation, gut health, and anti-inflammatory responses—to address inflammatory diseases like Inflammatory Bowel Disease (IBD).[1][2] Its initial product is a patented food formula that reduces inflammation and prolongs remission in IBD patients, targeting the $20.3B IBD market (projected CAGR 3.6% to 2030) within the $23B medical foods sector (CAGR 5.1% to 2030).[2] Exosomm serves patients with IBD and plans broader applications for inflammation, infection, and cancer, transforming dairy waste into scalable therapeutics via a chemical-free, patent-protected process.[1][2]
Exosomm emerged from deep academic research on milk-derived extracellular vesicles and their microRNA cargo, inspired by the health benefits of mother's milk.[1][2][4] Co-founded by Netta Granot (CEO), with 20 years in food industry R&D specializing in infant nutrition, plant-based proteins, and dairy, and Golan-Gerstl, PhD (CTO), a senior lecturer and director of the Pediatric Laboratory at Hadassah Medical Center focused on milk exosomes.[2] Supported by Galil Ofek Innovation, the company developed proven isolation protocols and protected IP, achieving early traction with its first anti-inflammatory food formula for IBD.[2] This backstory humanizes Exosomm as a bridge between nature's delivery systems and industrial biotech, starting from research at a leading medical center.
Exosomm stands out in the BioTech-FoodTech space through these key advantages:
Exosomm rides the wave of exosome therapeutics and precision nutrition, leveraging milk's natural vesicles amid rising demand for non-pharma anti-inflammatory solutions in a post-pandemic era of chronic gut diseases.[1][2] Timing is ideal as IBD prevalence surges (1.5% annual growth, concentrated in North America, Europe, China), aligning with the fast-expanding gastrointestinal medical foods segment.[2] Market forces like sustainability pressures in dairy and biotech's shift to scalable, natural biologics favor Exosomm's waste-to-wellness model, influencing the ecosystem by validating milk exosomes for nutrition—potentially disrupting $20B+ IBD treatments and inspiring FoodTech innovations in miRNA delivery.[1][2][4]
Exosomm is poised to capture share in the $23B medical foods market through commercialization of its IBD formula and platform expansion to new indications like cancer and infection.[2] Trends in personalized nutrition, sustainable biotech, and exosome scaling will propel growth, with partnerships accelerating global penetration. Its influence may evolve from niche FoodTech to ecosystem leader in natural therapeutics, redefining dairy byproducts as scalable wellness solutions—echoing its breakthrough in transforming nature's messengers into industrial reality.[1][2]
